Kevin Kalinsky

机构：Emory Healthcare, Emory University, Piedmont Cancer Institute, Sylvester Comprehensive Cancer Center, Winship Cancer Institute · ORCID：0000-0002-3113-7902

发表论文 387 篇 · 总被引 9227 次 · h-index 45

代表论文

• Abstract RF7-03: Updated results and an exploratory analysis of ESR1m circulating tumor DNA (ctDNA) dynamics from SERENA-6, a phase 3 trial of camizestrant (CAMI) + CDK4/6 inhibitor (CDK4/6i) for emergent ESR1 mutations (ESR1m) during first-line (1L) endocrine-based therapy and ahead of disease progression in patients (pts) with HR+/HER2- advanced breast cancer (ABC) (2026 · Clinical Cancer Research · 被引 4)
• Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women (2025 · JAMA Oncology · 被引 3)
• A Patient-Led Survey of Antibody Drug Conjugate Usage and Dosing for People Living With Metastatic Breast Cancer (2026 · Journal of Patient Experience · 被引 1)
• Ovarian reserve as a measure of adjuvant chemotherapy benefit in hormone receptor positive (HR-positive), HER2-negative, node-positive breast cancer in SWOG S1007 (RxPONDER) (2026 · Annals of Oncology)
• Data from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer (2026)
• Supplementary Figure 2 from Sociodemographic Disparities in First-Line Treatment and Outcome Patterns in Women with HR+/HER2− Metastatic Breast Cancer (2026)